BDgene Therapeutics

Executive Summary

BDgene Therapeutics is a clinical-stage biotech company headquartered in Shanghai, China, pioneering gene therapy for infectious diseases and oncology. Founded in 2018, the company leverages its proprietary exosome-based non-viral delivery platform to develop innovative genetic medicines. Its lead programs target HIV and solid tumors, addressing significant unmet medical needs. The exosome platform offers potential advantages over viral vectors, including reduced immunogenicity and improved tissue targeting, which could enable safer and more effective gene therapies. The company is currently in Phase 1 development, with early clinical data anticipated in the near term. BDgene's focus on HIV aligns with the global need for functional cures, while its oncology programs target difficult-to-treat solid tumors. As a private company with 50-200 employees, BDgene is well-positioned to advance its pipeline through strategic partnerships and regulatory interactions. The exosome-based delivery approach differentiates it from competitors and could unlock new therapeutic possibilities. However, given the early stage of development and inherent risks in gene therapy, conviction is moderate but supported by the novelty of the platform and the caliber of the science.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for lead HIV gene therapy candidate40% success
• Q2 2026IND filing or clearance for solid tumor gene therapy program60% success
• Q3 2026Strategic partnership or licensing deal for exosome delivery platform55% success